Special Patient Populations: Transplant Recipients

Clinical Lipidology: A Companion to Braunwald's Heart Disease

Volumn , Issue , 2009, Pages 486-499

  Holdaas, Hallvard ^a   Kobashigawa, Jon A ^b   Fellstrøm, Bengt ^c   Jardine, Alan G ^d  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77952563072     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-141605469-6.50044-5     Document Type: Chapter

References (220)

1. Collins AJ, Kasiske B, Herzog C, et al. Excerpts from the United States Renal Data System 2006 Annual Data Report. Am J Kidney Dis 2007, 49:S1-S296.
2. Holdaas H Preventing cardiovascular outcome in patients with renal impairment: Is there a role for lipid-lowering therapy?. Am J Cardiovasc Drugs 2005, 5:255-269.
3. Kasiske BL, Chakkera HA, Roel J Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 2000, 11:1735-1743.
4. Kobashigawa JA, Kasiske BL Hyperlipidemia in solid organ transplantation. Transplantation 1997, 63:331-338.
5. Bostom AD, Brown RS, Chavers BM, et al. Prevention of posttransplant cardiovascular disease-report and recommendations of an ad hoc group. Am J Transpl 2002, 2:491-500.
6. Guckelberger O, Byram A, Klupp J, et al. Coronary event rates in liver transplant recipients reflect the increased prevalence of cardiovascular risk-factors. Transpl Int 2005, 18:967-974.
7. Johnston SD, Morris JK, Cramb R, et al. Cardiovascular morbidity and mortality after orthotopic liver transplantation. Transplantation 2002, 73:901-906.
8. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-1278.
9. Holdaas H, Fellstrom B, Cole E, et al. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. Am J Transpl 2005, 5:2929-2936.
10. Holdaas H, Fellstrom B, Jardine AG, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003, 361:2024-2031.
11. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995, 333:621-627.
12. Kobashigawa JA, Moriguchi JD, Laks H, et al. Ten-year followup of a randomized trial of pravastatin in heart transplant patients. J Heart Lung Transpl 2005, 24:1736-1740.
13. Wenke K, Meiser B, Thiery J, et al. Simvastatin initiated early after heart transplantation: 8-year prospective experience. Circulation 2003, 107:93-97.
14. Fellstrom B, Jardine AG, Soveri I, et al. Renal dysfunction as a risk factor for mortality and cardiovascular disease in renal transplantation: experience from the Assessment of Lescol in Renal Transplantation trial. Transplantation 2005, 79:1160-1163.
15. Fellstrom B, Jardine AG, Soveri I, et al. Renal dysfunction is a strong and independent risk factor for mortality and cardiovascular complications in renal transplantation. Am J Transpl 2005, 5:1986-1991.
16. Fernandez-Fresnedo G, Escallada R, Rodrigo E, et al. The risk of cardiovascular disease associated with proteinuria in renal transplant patients. Transplantation 2002, 73:1345-1348.
17. Kasiske BL, Umen AJ Persistent hyperlipidemia in renal transplant patients. Medicine (Baltimore) 1987, 66:309-316.
18. Burrell DE, Antignani A, Goldwasser P, et al. Lipid abnormalities in black renal patients. N Y State J Med 1991, 91:192-196.
19. Kasiske BL Risk factors for cardiovascular disease after renal transplantation. Miner Electrolyte Metab 1993, 19:186-195.
20. Aakhus S, Dahl K, Wideroe TE Hyperlipidaemia in renal transplant patients. J Intern Med 1996, 239:407-415.
21. Dimeny E, Wahlberg J, Lithell H, et al. Hyperlipidaemia in renal transplantation-risk factor for long-term graft outcome. Eur J Clin Invest 1995, 25:574-583.
22. Drueke TB, Abdulmassih Z, Lacour B, et al. Atherosclerosis and lipid disorders after renal transplantation. Kidney Int Suppl 1991, 31:S24-S28.
23. Moore R, Thomas D, Morgan E, et al. Abnormal lipid and lipoprotein profiles following renal transplantation. Transpl Proc 1993, 25:1060-1061.
24. Pannu HS, Singh D, Sandhu JS Lipid profile before and after renal transplantation-a longitudinal study. Ren Fail 2003, 25:411-417.
25. Appel G Lipid abnormalities in renal disease. Kidney Int 1991, 39:169-183.
26. Rao VK Posttransplant medical complications. Surg Clin North Am 1998, 78:113-132.
27. Tse KC, Lam MF, Yip PS, et al. A long-term study on hyperlipidemia in stable renal transplant recipients. Clin Transpl 2004, 18:274-280.
28. Vathsala A, Weinberg RB, Schoenberg L, et al. Lipid abnormalities in cyclosporine-prednisone-treated renal transplant recipients. Transplantation 1989, 48:37-43.
29. Coresh J, Longenecker JC, Miller ER, et al. Epidemiology of cardiovascular risk factors in chronic renal disease. J Am Soc Nephrol 1998, 9:S24-S30.
30. Hilbrands LB, Demacker PN, Hoitsma AJ, et al. The effects of cyclosporine and prednisone on serum lipid and (apo)lipoprotein levels in renal transplant recipients. J Am Soc Nephrol 1995, 5:2073-2081.
31. Jung K, Scheifler A, Blank W, et al. Changed composition of high-density lipoprotein subclasses HDL2 and HDL3 after renal transplantation. Transplantation 1988, 46:407-409.
32. Fellstrom B Impact and management of hyperlipidemia posttransplantation. Transplantation 2000, 70:SS51-SS57.
33. Ghanem H, van den Dorpel MA, Weimar W, et al. Increased low-density lipoprotein oxidation in stable kidney transplant recipients. Kidney Int 1996, 49:488-493.
34. Siirtola A, Ketomaki A, Miettinen TA, et al. Cholesterol absorption and synthesis in pediatric kidney, liver, and heart transplant recipients. Transplantation 2006, 81:327-334.
35. Kasiske BL Hyperlipidemia in patients with chronic renal disease. Am J Kidney Dis 1998, 32:S142-S156.
36. Cattran DC, Steiner G, Wilson DR, et al. Hyperlipidemia after renal transplantation: natural history and pathophysiology. Ann Intern Med 1979, 91:554-559.
37. Ponticelli C, Barbi GL, Cantaluppi A, et al. Lipid disorders in renal transplant recipients. Nephron 1978, 20:189-195.
38. Pascual J, van Hooff JP, Salmela K, et al. Three-year observational follow-up of a multicenter, randomized trial on tacrolimus-based therapy with withdrawal of steroids or mycophenolate mofetil after renal transplant. Transplantation 2006, 82:55-61.
39. Vanrenterghem Y, van Hooff JP, Squifflet JP, et al. Minimization of immunosuppressive therapy after renal transplantation: results of a randomized controlled trial. Am J Transpl 2005, 5:87-95.
40. Jardine AG Assessing the relative risk of cardiovascular disease among renal transplant patients receiving tacrolimus or cyclosporine. Transpl Int 2005, 18:379-384.
41. Kirk JK, Dupuis RE Approaches to the treatment of hyperlipidemia in the solid organ transplant recipient. Ann Pharmacother 1995, 29:879-891.
42. Ligtenberg G, Hene RJ, Blankestijn PJ, et al. Cardiovascular risk factors in renal transplant patients: cyclosporin A versus tacrolimus. J Am Soc Nephrol 2001, 12:368-373.
43. Kasiske BL, Tortorice KL, Heim-Duthoy KL, et al. The adverse impact of cyclosporine on serum lipids in renal transplant recipients. Am J Kidney Dis 1991, 17:700-707.
44. Al Rayyes O, Wallmark A, Florén CH Additive inhibitory effect of hydrocortisone and cyclosporine on low-density lipoprotein eceptor activity in cultured HepG2 cells. Hepatology 1997, 26:967-971.
45. Rayyes OA, Wallmark A, Floren CH Cyclosporine inhibits catabolism of low-density lipoproteins in HepG2 cells by about 25%. Hepatology 1996, 24:613-619.
46. Vaziri ND, Liang K, Azad H Effect of cyclosporine on HMG-CoA reductase, cholesterol 7alpha-hydroxylase, LDL receptor, HDL receptor, VLDL receptor, and lipoprotein lipase expressions. J Pharmacol Exp Ther 2000, 294:778-783.
47. McCashland TM, Donovan JP, Amelsberg A, et al. Bile acid metabolism and biliary secretion in patients receiving orthotopic liver transplants: differing effects of cyclosporine and FK 506. Hepatology 1994, 19:1381-1389.
48. Mathis AS, Dave N, Knipp GT, et al. Drug-related dyslipidemia after renal transplantation. Am J Health Syst Pharm 2004, 61:565-585.
49. McCune TR, Thacker LR, Peters TG, et al. Effects of tacrolimus on hyperlipidemia after successful renal transplantation: a Southeastern Organ Procurement Foundation multicenter clinical study. Transplantation 1998, 65:87-92.
50. Urbizu JM, Amenabar JJ, Gomez-Ullate P, et al. Immunosuppression using tacrolimus/mycophenolate versus neoral/mycophenolate following kidney transplantation: a singlecenter experience. Transpl Proc 2002, 34:87-88.
51. Wissing KM, Unger P, Ghisdal L, et al. Effect of atorvastatin therapy and conversion to tacrolimus on hypercholesterolemia and endothelial dysfunction after renal transplantation. Transplantation 2006, 82:771-778.
52. MacDonald AS A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001, 71:271-280.
53. Neumayer HH, Paradis K, Korn A, et al. Entry-into-human study with the novel immunosuppressant SDZ RAD in stable renal transplant recipients. Br J Clin Pharmacol 1999, 48:694-703.
54. Vitko S, Tedesco H, Eris J, et al. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. Am J Transpl 2004, 4:626-635.
55. Hoogeveen RC, Ballantyne CM, Pownall HJ, et al. Effect of sirolimus on the metabolism of apo. Transplantation 2001, 72:1244-1250.
56. Morrisett JD, bdel-Fattah G, Hoogeveen R, et al. Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. J Lipid Res 2002, 43:1170-1180.
57. Groth CG, Backman L, Morales JM, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999, 67:1036-1042.
58. Blum CB Effects of sirolimus on lipids in renal allograft recipients: an analysis using the Framingham risk model. Am J Transpl 2002, 2:551-559.
59. Miller LW Cardiovascular toxicities of immunosuppressive agents. Am J Transpl 2002, 2:807-818.
60. Stegall MD, Wachs ME, Everson G, et al. Prednisone withdrawal 14 days after liver transplantation with mycophenolate: a prospective trial of cyclosporine and tacrolimus. Transplantation 1997, 64:1755-1760.
61. Ducloux D, Fournier V, Bresson-Vautrin C, et al. Mycophenolate mofetil in renal transplant recipients with cyclosporineassociated nephrotoxicity: a preliminary report. Transplantation 1998, 65:1504-1506.
62. Briggs JD Causes of death after renal transplantation. Nephrol Dial Transpl 2001, 16:1545-1549.
63. Foley RN, Parfrey PS, Sarnak MJ Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998, 32:S112-S119.
64. Aakhus S, Dahl K, Wideroe TE Cardiovascular disease in stable renal transplant patients in Norway: morbidity and mortality during a 5-yr follow-up. Clin Transpl 2004, 18:596-604.
65. Lindholm A, Albrechtsen D, Frodin L, et al. Ischemic heart disease-major cause of death and graft loss after renal transplantation in Scandinavia. Transplantation 1995, 60:451-457.
66. Madsen M, Jespersen B, Lokkegaard H, et al: Kidney transplantation activity and outcome in Denmark 1990-1999. Clin Transpl 2000;357-358.
67. Ojo AO, Hanson JA, Wolfe RA, et al. Long-term survival in renal transplant recipients with graft function. Kidney Int 2000, 57:307-313.
68. Kasiske BL, Maclean JR, Snyder JJ Acute myocardial infarction and kidney transplantation. J Am Soc Nephrol 2006, 17:900-907.
69. Aker S, Ivens K, Guo Z, et al. Cardiovascular complications after renal transplantation. Transpl Proc 1998, 30:2039-2042.
70. Bumgardner GL, Wilson GA, Tso PL, et al. Impact of serum lipids on long-term graft and patient survival after renal transplantation. Transplantation 1995, 60:1418-1421.
71. Hillebrand GF, Schlosser S, Schneeberger H, et al. No clinical evidence of hyperlipidemia as a risk factor for chronic renal allograft failure. Transpl Proc 1999, 31:1391-1392.
72. Kasiske BL, Guijarro C, Massy ZA, et al. Cardiovascular disease after renal transplantation. J Am Soc Nephrol 1996, 7:158-165.
73. Ong CS, Pollock CA, Caterson RJ, et al. Hyperlipidemia in renal transplant recipients: natural history and response to treatment. Medicine (Baltimore) 1994, 73:215-223.
74. Pollock CA, Mahony JF, Ong CS, et al. Hyperlipidemia in renal transplant recipients: does it matter and can we treat it?. Transpl Proc 1995, 27:2152-2153.
75. Roodnat JI, Mulder PG, Zietse R, et al. Cholesterol as an independent predictor of outcome after renal transplantation. Transplantation 2000, 69:1704-1710.
76. Jardine AG, Holdaas H, Fellstrom B, et al. Fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post-hoc subgroup analyses of the ALERT Study. Am J Transpl 2004, 4:988-995.
77. Holdaas H, Fellstrom B, Holme I, et al. Effects of fluvastatin on cardiac events in renal transplant patients: ALERT (Assessment of Lescol in Renal Transplantation) study design and baseline data. J Cardiovasc Risk 2001, 8:63-71.
78. Soveri I, Holdaas H, Jardine A, et al. Renal transplant dysfunction-importance quantified in comparison with traditional risk factors for cardiovascular disease and mortality. Nephrol Dial Transpl 2006, 21:2282-2289.
79. Abbott KC, Bucci JR, Cruess D, et al. Graft loss and acute coronary syndromes after renal transplantation in the United States. J Am Soc Nephrol 2002, 13:2560-2569.
80. Abbott KC, Yuan CM, Taylor AJ, et al. Early renal insufficiency and hospitalized heart disease after renal transplantation in the era of modern immunosuppression. J Am Soc Nephrol 2003, 14:2358-2365.
81. Fellstrom B, Holdaas H, Jardine AG, et al. Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial. Kidney Int 2004, 66:1549-1555.
82. Gill JS, Abichandani R, Kausz AT, et al. Mortality after kidney transplant failure: the impact of non-immunologic factors. Kidney Int 2002, 62:1875-1883.
83. Woo YM, McLean D, Kavanagh D, et al. The influence of preoperative electrocardiographic abnormalities and cardiovascular risk factors on patient and graft survival following renal transplantation. J Nephrol 2002, 15:380-386.
84. Foldes K, Maklary E, Vargha P, et al. Effect of diet and fluvastatin treatment on the serum lipid profile of kidney transplant, diabetic recipients: a 1-year follow up. Transpl Int 1998, 11(suppl 1):S65-S68.
85. Massy ZA, Ma JZ, Louis TA, et al. Lipid-lowering therapy in patients with renal disease. Kidney Int 1995, 48:188-198.
86. Tonstad S, Holdaas H, Gorbitz C, et al. Is dietary intervention effective in post-transplant hyperlipidaemia?. Nephrol Dial Transpl 1995, 10:82-85.
87. Painter PL, Hector L, Ray K, et al. Effects of exercise training on coronary heart disease risk factors in renal transplant recipients. Am J Kidney Dis 2003, 42:362-369.
88. Keogh A, Day R, Critchley L, et al. The effect of food and cholestyramine on the absorption of cyclosporine in cardiac transplant recipients. Transpl Proc 1988, 20:27-30.
89. Jensen RA, Lal SM, az-Arias A, et al. Does cholestyramine interfere with cyclosporine absorption? A prospective study in renal transplant patients. ASAIO J 1995, 41:M704-M706.
90. Ballantyne CM, Corsini A, Davidson MH, et al. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med 2003, 163:553-564.
91. Lal SM, Hewett JE, Petroski GF, et al. Effects of nicotinic acid and lovastatin in renal transplant patients: a prospective, randomized, open-labeled crossover trial. Am J Kidney Dis 1995, 25:616-622.
92. Parra JL, Reddy KR Hepatotoxicity of hypolipidemic drugs. Clin Liver Dis 2003, 7:415-433.
93. Vogt A, Kassner U, Hostalek U, et al. Evaluation of the safety and tolerability of prolonged-release nicotinic acid in a usual care setting: The NAUTILUS study. Curr Med Res Opin 2006, 22:417-425.
94. Launay-Vacher V, Izzedine H, Deray G Statins' dosage in patients with renal failure and cyclosporine drug-drug interactions in transplant recipient patients. Int J Cardiol 2005, 101:9-17.
95. Samman A, Imai C, Straatman L, et al. Safety and efficacy of rosuvastatin therapy for the prevention of hyperlipidemia in adult cardiac transplant recipients. J Heart Lung Transpl 2005, 24:1008-1013.
96. Asberg A, Hartmann A, Fjeldsa E, et al. Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients. Am J Transpl 2001, 1:382-386.
97. Asberg A, Holdaas H, Jardine AG, et al. Fluvastatin reduces atherogenic lipids without any effect on native endothelial function early after kidney transplantation. Clin Transpl 2003, 17:385-390.
98. Gullestad L, Nordal KP, Berg KJ, et al. Interaction between lovastatin and cyclosporine A after heart and kidney transplantation. Transpl Proc 1999, 31:2163-2165.
99. Hermann M, Asberg A, Christensen H, et al. Substantially elevated levels of atorvastatin and metabolites in cyclosporine-treated renal transplant recipients. Clin Pharmacol Ther 2004, 76:388-391.
100. Hermann M, Asberg A, Christensen H, et al. Atorvastatin does not affect the pharmacokinetics of cyclosporine in renal transplant recipients. Eur J Clin Pharmacol 2005, 61:59-62.
101. Holdaas H, Hagen E, Asberg A, et al. Evaluation of the pharmacokinetic interaction between fluvastatin XL and cyclosporine in renal transplant recipients. Int J Clin Pharmacol Ther 2006, 44:163-171.
102. Holdaas H, Hartmann A, Stenstrom J, et al. Effect of fluvastatin for safely lowering atherogenic lipids in renal transplant patients receiving cyclosporine. Am J Cardiol 1995, 76:102A-106A.
103. Holdaas H, Jardine AG, Wheeler DC, et al. Effect of fluvastatin on acute renal allograft rejection: a randomized multicenter trial. Kidney Int 2001, 60:1990-1997.
104. Imamura R, Ichimaru N, Moriyama T, et al. Long term efficacy of simvastatin in renal transplant recipients treated with cyclosporine or tacrolimus. Clin Transpl 2005, 19:616-621.
105. Kobashigawa JA, Murphy FL, Stevenson LW, et al. Low-dose lovastatin safely lowers cholesterol after cardiac transplantation. Circulation 1990, 82:IV281-IV283.
106. Lemahieu WP, Hermann M, Asberg A, et al. Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus. Am J Transpl 2005, 5:2236-2243.
107. Martinez-Castelao A, Grinyo JM, Gil-Vernet S, et al. Lipidlowering long-term effects of six different statins in hypercholesterolemic renal transplant patients under cyclosporine immunosuppression. Transpl Proc 2002, 34:398-400.
108. Rehman MA, al-Sulaiman MH, Mousa DH, et al. Effects of simvastatin in hyperlipidemic renal transplant patients receiving cyclosporine. Transplantation 1995, 60:397-399.
109. Yoshimura N, Oka T, Okamoto M, et al. The effects of pravastatin on hyperlipidemia in renal transplant recipients. Transplantation 1992, 53:94-99.
110. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Final report. Circulation 2002, 106:3143-3421.
111. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227-239.
112. Smith SC, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol 2006, 47:2130-2139.
113. Kasiske B, Cosio FG, Beto J, et al. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Transpl 2004, 4(suppl 7):13-53.
114. Sudhop T, Lutjohann D, Kodal A, et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 2002, 106:1943-1948.
115. Bergman AJ, Burke J, Larson P, et al. Interaction of single-dose ezetimibe and steady-state cyclosporine in renal transplant patients. J Clin Pharmacol 2006, 46:328-336.
116. Bilchick KC, Henrikson CA, Skojec D, et al. Treatment of hyperlipidemia in cardiac transplant recipients. Am Heart J 2004, 148:200-210.
117. Buchanan C, Smith L, Corbett J, et al. A retrospective analysis of ezetimibe treatment in renal transplant recipients. Am J Transpl 2006, 6:770-774.
118. Gazi IF, Liberopoulos EN, Athyros VG, et al. Statins and solid organ transplantation. Curr Pharm Des 2006, 12:4771-4783.
119. Kohnle M, Pietruck F, Kribben A, et al. Ezetimibe for the treatment of uncontrolled hypercholesterolemia in patients with high-dose statin therapy after renal transplantation. Am J Transpl 2006, 6:205-208.
120. Koshman SL, Lalonde LD, Burton I, et al. Supratherapeutic response to ezetimibe administered with cyclosporine. Ann Pharmacother 2005, 39:1561-1565.
121. Langone AJ, Chuang P Ezetimibe in renal transplant patients with hyperlipidemia resistant to HMG-CoA reductase inhibitors. Transplantation 2006, 81:804-807.
122. Panichi V, Manca-Rizza G, Paoletti S, et al. Safety and effects on the lipid and C-reactive protein plasma concentration of the association of ezetimibe plus atorvastatin in renal transplant patients treated by cyclosporine-A: a pilot study. Biomed Pharmacother 2006, 60:249-252.
123. Patel AR, Ambrose MS, Duffy GA, et al. Treatment of hypercholesterolemia with ezetimibe in cardiac transplant recipients. J Heart Lung Transpl 2007, 26:281-284.
124. Puthenparumpil JJ, Keough-Ryan T, Kiberd M, et al. Treatment of hypercholesterolemia with ezetimibe in the kidney transplant population. Transpl Proc 2005, 37:1033-1035.
125. Bays HE, Dujovne CA Drugs for treatment of patients with high cholesterol blood levels and other dyslipidemias. Prog Drug Res 1994, 43:9-41.
126. Tatsioni A, Chung M, Sun Y, et al. Effects of fish oil supplementation on kidney transplantation: a systematic review and meta-analysis of randomized, controlled trials. J Am Soc Nephrol 2005, 16:2462-2470.
127. Thervet E, Legendre C, Beaune P, et al. Cytochrome P450 3A polymorphisms and immunosuppressive drugs. Pharmacogenomics 2005, 6:37-47.
128. Asberg A Interactions between cyclosporin and lipid-lowering drugs: implications for organ transplant recipients. Drugs 2003, 63:367-378.
129. Zhang Y, Benet LZ The gut as a barrier to drug absorption: Combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet 2001, 40:159-168.
130. Bramow S, Ott P, Thomsen NF, et al. Cholestasis and regulation of genes related to drug metabolism and biliary transport in rat liver following treatment with cyclosporine A and sirolimus (Rapamycin). Pharmacol Toxicol 2001, 89:133-139.
131. Akhlaghi F, McLachlan AJ, Keogh AM, et al. Effect of simvastatin on cyclosporine unbound fraction and apparent blood clearance in heart transplant recipients. Br J Clin Pharmacol 1997, 44:537-542.
132. Olbricht C, Wanner C, Eisenhauer T, et al. Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporinetreated kidney graft patients after multiple doses. Clin Pharmacol Ther 1997, 62:311-321.
133. Regazzi MB, Iacona I, Campana C, et al. Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients. Transpl Proc 1993, 25:2732-2734.
134. Arnadottir M, Eriksson LO, Thysell H, et al. Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin. Nephron 1993, 65:410-413.
135. Goldberg R, Roth D Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporine. Transplantation 1996, 62:1559-1564.
136. Corpier CL, Jones PH, Suki WN, et al. Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients. JAMA 1988, 260:239-241.
137. Corsini A, Holdaas H Fluvastatin in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantation. Ren Fail 2005, 27:259-273.
138. East C, Alivizatos PA, Grundy SM, et al. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. N Engl J Med 1988, 318:47-48.
139. Grekas D, Kassimatis E, Makedou A, et al. Combined treatment with low-dose pravastatin and fish oil in post-renal transplantation dislipidemia. Nephron 2001, 88:329-333.
140. Gumprecht J, Zychma M, Grzeszczak W, et al. Simvastatininduced rhabdomyolysis in a CsA-treated renal transplant recipient. Med Sci Monit 2003, 9:CS89-CS91.
141. Kotanko P, Kirisits W, Skrabal F Rhabdomyolysis and acute renal graft impairment in a patient treated with simvastatin, tacrolimus, and fusidic acid. Nephron 2002, 90:234-235.
142. Kusus M, Stapleton DD, Lertora JJ, et al. Rhabdomyolysis and acute renal failure in a cardiac transplant recipient due to multiple drug interactions. Am J Med Sci 2000, 320:394-397.
143. Maltz HC, Balog DL, Cheigh JS Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporine. Ann Pharmacother 1999, 33:1176-1179.
144. Rodriguez JA, Crespo-Leiro MG, Paniagua MJ, et al. Rhabdomyolysis in heart transplant patients on HMG-CoA reductase inhibitors and cyclosporine. Transpl Proc 1999, 31:2522-2523.
145. Rodriguez ML, Mora C, Navarro JF Cerivastatin-induced rhabdomyolysis. Ann Intern Med 2000, 132:598.
146. Segaert MF, De SC, Vandewiele I, et al. Drug-interaction-induced rhabdomyolysis. Nephrol Dial Transpl 1996, 11:1846-1847.
147. Stirling CM, Isles CG Rhabdomyolysis due to simvastatin in a transplant patient: are some statins safer than others?. Nephrol Dial Transpl 2001, 16:873-874.
148. Stirling CM, Isles CG Rhabdomyolysis due to simvastatin in a transplant patient: are some statins safer than others?. Nephrol Dial Transpl 2001, 16:873-874.
149. Weise WJ, Possidente CJ Fatal rhabdomyolysis associated with simvastatin in a renal transplant patient. Am J Med 2000, 108:351-352.
150. Cosio FG, Pesavento TE, Pelletier RP, et al. Patient survival after renal transplantation III: the effects of statins. Am J Kidney Dis 2002, 40:638-643.
151. Holdaas H, Fellstrom B, Jardine AG, et al. Beneficial effect of early initiation of lipid-lowering therapy following renal transplantation. Nephrol Dial Transpl 2005, 20:974-980.
152. Hamar P, Muller V, Kohnle M, et al. Metabolic factors have a major impact on kidney allograft survival. Transplantation 1997, 64:1135-1139.
153. Isoniemi H, Nurminen M, Tikkanen MJ, et al. Risk factors predicting chronic rejection of renal allografts. Transplantation 1994, 57:68-72.
154. Katznelson S, Wilkinson AH, Kobashigawa JA, et al. The effect of pravastatin on acute rejection after kidney transplantation-a pilot study. Transplantation 1996, 61:1469-1474.
155. Masterson R, Hewitson T, Leikis M, et al. Impact of statin treatment on 1-year functional and histologic renal allograft outcome. Transplantation 2005, 80:332-338.
156. Tuncer M, Suleymanlar G, Ersoy FF, et al. Comparison of the effects of simvastatin and pravastatin on acute rejection episodes in renal transplant patients. Transpl Proc 2000, 32:622-625.
157. Kwak B, Mulhaupt F, Myit S, et al. Statins as a newly recognized type of immunomodulator. Nat Med 2000, 6:1399-1402.
158. Weitz-Schmidt G, Welzenbach K, Brinkmann V, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001, 7:687-692.
159. Holdaas H, Jardine A Acute renal allograft rejections, a role for statins?. Minerva Urol Nefrol 2003, 55:111-119.
160. Kasiske BL, Heim-Duthoy KL, Singer GG, et al. The effects of lipid-lowering agents on acute renal allograft rejection. Transplantation 2001, 72:223-227.
161. Sahu K, Sharma R, Gupta A, et al. Effect of lovastatin, an HMG CoA reductase inhibitor, on acute renal allograft rejection. Clin Transpl 2001, 15:173-175.
162. Lentine KL, Brennan DC Statin use after renal transplantation: a systematic quality review of trial-based evidence. Nephrol Dial Transpl 2004, 19:2378-2386.
163. Stamler JS, Vaughan DE, Rudd MA, et al. Frequency of hypercholesterolemia after cardiac transplantation. Am J Cardiol 1988, 62:1268-1272.
164. Taylor DO, Edwards LB, Boucek MM, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult heart transplantation report-2006. J Heart Lung Transpl 2006, 25:869-879.
165. Valantine HA Role of lipids in allograft vascular disease: a multicenter study of intimal thickening detected by intravascular ultrasound. J Heart Lung Transpl 1995, 14:S234-S237.
166. Eich D, Thompson JA, Ko DJ, et al. Hypercholesterolemia in long-term survivors of heart transplantation: an early marker of accelerated coronary artery disease. J Heart Lung Transpl 1991, 10:45-49.
167. Kapadia SR, Nissen SE, Ziada KM, et al. Impact of lipid abnormalities in development and progression of transplant coronary disease: a serial intravascular ultrasound study. J Am Coll Cardiol 2001, 38:206-213.
168. Kobashigawa JA, Tobis JM, Starling RC, et al. Multicenter intravascular ultrasound validation study among heart transplant recipients: outcomes after five years. J Am Coll Cardiol 2005, 45:1532-1537.
169. Kobashigawa JA, Starling RC, Mehra MR, et al. Multicenter retrospective analysis of cardiovascular risk factors affecting long-term outcome of de novo cardiac transplant recipients. J Heart Lung Transpl 2006, 25:1063-1069.
170. White M, Haddad H, Leblanc MH, et al. Conversion from cyclosporine microemulsion to tacrolimus-based immunoprophylaxis improves cholesterol profile in heart transplant recipients with treated but persistent dyslipidemia: the Canadian multicentre randomized trial of tacrolimus vs cyclosporine microemulsion. J Heart Lung Transpl 2005, 24:798-809.
171. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiactransplant recipients. N Engl J Med 2003, 349:847-858.
172. Keogh A, Richardson M, Ruygrok P, et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation 2004, 110:2694-2700.
173. Wenke K, Meiser B, Thiery J, et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation: four-year randomized trial. Circulation 1997, 96:1398-1402.
174. Weis M, Pehlivanli S, Meiser BM, et al. Simvastatin treatment is associated with improvement in coronary endothelial function and decreased cytokine activation in patients after heart transplantation. J Am Coll Cardiol 2001, 38:814-818.
175. Wu AH, Ballantyne CM, Short BC, et al. Statin use and risks of death or fatal rejection in the Heart Transplant Lipid Registry. Am J Cardiol 2005, 95:367-372.
176. Wenke K Management of hyperlipidaemia associated with heart transplantation. Drugs 2004, 64:1053-1068.
177. Regazzi MB, Iacona I, Campana C, et al. Clinical efficacy and pharmacokinetics of HMG-CoA reductase inhibitors in heart transplant patients treated with cyclosporin A. Transpl Proc 1994, 26:2644-2645.
178. McPherson R, Tsoukas C, Baines MG, et al. Effects of lovastatin on natural killer cell function and other immunological parameters in man. J Clin Immunol 1993, 13:439-444.
179. Palinski W, Tsimikas S Immunomodulatory effects of statins: mechanisms and potential impact on arteriosclerosis. J Am Soc Nephrol 2002, 13:1673-1681.
180. Napoli C, de Nigris F, Palinski W Multiple role of reactive oxygen species in the arterial wall. J Cell Biochem 2001, 82:674-682.
181. Laufs U, Liao JK Direct vascular effects of HMG-CoA reductase inhibitors. Trends Cardiovasc Med 2000, 10:143-148.
182. Liu L, Moesner P, Kovach NL, et al. Integrin-dependent leukocyte adhesion involves geranylgeranylated protein(s). J Biol Chem 1999, 274:33334-33340.
183. Essig M, Nguyen G, Prie D, et al. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins. Circ Res 1998, 83:683-690.
184. Wassmann S, Laufs U, Baumer AT, et al. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 2001, 37:1450-1457.
185. Endres M, Laufs U, Huang Z, et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci U S A 1998, 95:8880-8885.
186. Guijarro C, Blanco-Colio LM, Ortego M, et al. 3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ Res 1998, 83:490-500.
187. Si MS, Ji P, Tromberg BJ, et al. Farnesyltransferase inhibition: a novel method of immunomodulation. Int Immunopharmacol 2003, 3:475-483.
188. Gisbert C, Prieto M, Berenguer M, et al. Hyperlipidemia in liver transplant recipients: prevalence and risk factors. Liver Transpl Surg 1997, 3:416-422.
189. Guckelberger O, Bechstein WO, Neuhaus R, et al. Cardiovascular risk factors in long-term follow-up after orthotopic liver transplantation. Clin Transpl 1997, 11:60-65.
190. Guckelberger O, Mutzke F, Glanemann M, et al. Validation of cardiovascular risk scores in a liver transplant population. Liver Transpl 2006, 12:394-401.
191. Mathe D, Adam R, Malmendier C, et al. Prevalence of dyslipidemia in liver transplant recipients. Transplantation 1992, 54:167-170.
192. Neal DA, Alexander GJ Can the potential benefits of statins in general medical practice be extrapolated to liver transplantation?. Liver Transpl 2001, 7:1009-1014.
193. Reuben A Long-term management of the liver transplant patient: diabetes, hyperlipidemia, and obesity. Liver Transpl 2001, 7:S13-S21.
194. Sethi A, Stravitz RT Review article: medical management of the liver transplant recipient-a primer for non-transplant doctors. Aliment Pharmacol Ther 2007, 25:229-245.
195. Munoz SJ Hyperlipidemia and other coronary risk factors after orthotopic liver transplantation: pathogenesis, diagnosis, and management. Liver Transpl Surg 1995, 1:29-38.
196. Abbasoglu O, Levy MF, Brkic BB, et al. Ten years of liver transplantation: an evolving understanding of late graft loss. Transplantation 1997, 64:1801-1807.
197. Appleton CP, Hurst RT, Lee KS, et al. Long-term cardiovascular risk in the orthotopic liver transplant population. Liver Transpl 2006, 12:352-355.
198. Fernandez-Miranda C, de la CA, Morales JM, et al. Lipoprotein abnormalities in long-term stable liver and renal transplanted patients. A comparative study. Clin Transpl 1998, 12:136-141.
199. Neuberger J Liver transplantation. J Hepatol 2000, 32:198-207.
200. Imagawa DK, Dawson S, Holt CD, et al. Hyperlipidemia after liver transplantation: natural history and treatment with the hydroxy-methylglutaryl-coenzyme A reductase inhibitor pravastatin. Transplantation 1996, 62:934-942.
201. Taylor PJ, Kubler PA, Lynch SV, et al. Effect of atorvastatin on cyclosporine pharmacokinetics in liver transplant recipients. Ann Pharmacother 2004, 38:205-208.
202. Zachoval R, Gerbes AL, Schwandt P, et al. Short-term effects of statin therapy in patients with hyperlipoproteinemia after liver transplantation: results of a randomized cross-over trial. J Hepatol 2001, 35:86-91.
203. Singh TP, Naftel DC, Webber S, et al. Hyperlipidemia in children after heart transplantation. J Heart Lung Transpl 2006, 25:1199-1205.
204. Goldstein S, Duhamel G, Laudat MH, et al. Plasma lipids, lipoproteins and apolipoproteins AI, AII, and B in renal transplanted children: what risk for accelerated atherosclerosis?. Nephron 1984, 38:87-92.
205. Saland JM, Ginsberg H, Fisher EA Dyslipidemia in pediatric renal disease: epidemiology, pathophysiology, and management. Curr Opin Pediatr 2002, 14:197-204.
206. Silverstein DM Indications and outcome of treatment of hyperlipidemia in pediatric allograft recipients. Pediatr Transpl 2003, 7:7-10.
207. Silverstein DM, Palmer J, Polinsky MS, et al. Risk factors for hyperlipidemia in long-term pediatric renal transplant recipients. Pediatr Nephrol 2000, 14:105-110.
208. Hyams JS, Treem WR, Andrews WS, et al. Lipid abnormalities in pediatric hepatic allograft recipients. J Pediatr Gastroenterol Nutr 1989, 9:441-444.
209. McDiarmid SV, Gornbein JA, Fortunat M, et al. Serum lipid abnormalities in pediatric liver transplant patients. Transplantation 1992, 53:109-115.
210. Argent E, Kainer G, Aitken M, et al. Atorvastatin treatment for hyperlipidemia in pediatric renal transplant recipients. Pediatr Transpl 2003, 7:38-42.
211. Butani L Prospective monitoring of lipid profiles in children receiving pravastatin preemptively after renal transplantation. Pediatr Transpl 2005, 9:746-753.
212. Butani L, Pai MV, Makker SP Pilot study describing the use of pravastatin in pediatric renal transplant recipients. Pediatr Transpl 2003, 7:179-184.
213. Krmar RT, Ferraris JR, Ramirez JA, et al. Use of atorvastatin in hyperlipidemic hypertensive renal transplant recipients. Pediatr Nephrol 2002, 17:540-543.
214. Chin C, Gamberg P, Miller J, et al. Efficacy and safety of atorvastatin after pediatric heart transplantation. J Heart Lung Transpl 2002, 21:1213-1217.
215. Chin C, Rosenthal D, Bernstein D Lipoprotein abnormalities are highly prevalent in pediatric heart transplant recipients. Pediatr Transpl 2000, 4:193-199.
216. Hedman M, Neuvonen PJ, Neuvonen M, et al. Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression. Clin Pharmacol Ther 2004, 75:101-109.
217. Mahle WT, Vincent RN, Berg AM, et al. Pravastatin therapy is associated with reduction in coronary allograft vasculopathy in pediatric heart transplantation. J Heart Lung Transpl 2005, 24:63-66.
218. Penson MG, Fricker FJ, Thompson JR, et al. Safety and efficacy of pravastatin therapy for the prevention of hyperlipidemia in pediatric and adolescent cardiac transplant recipients. J Heart Lung Transpl 2001, 20:611-618.
219. Seipelt IM, Crawford SE, Rodgers S, et al. Hypercholesterolemia is common after pediatric heart transplantation: initial experience with pravastatin. J Heart Lung Transpl 2004, 23:317-322.
220. Stefanutti C, Lucani G, Vivenzio A, et al. Diet only and diet plus simvastatin in the treatment of heterozygous familial hypercholesterolemia in childhood. Drugs Exp Clin Res 1999, 25:23-28.